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See Article, pages 587–593Globally, chronic infection with hepatitis B virus (HBV) remains a
leading cause of liver related mortality [1]. Liver transplantation
(LT) provides a life saving therapy for HBV-infected patients with
complications of end stage liver disease and hepatocellular carci-
noma (HCC). Although chronic HBV infection is a declining indi-
cation for LT in the United States, chronic HBV remains the
leading indication for LT in Asia [2,3]. Prior to the early 1990’s,
reinfection with HBV after transplantation occurred in greater
than 80% of graft recipients and the 5-year graft and patient sur-
vival rates were only 50%. However, over the past two decades,
signiﬁcant advances in both prevention and treatment of recur-
rent HBV disease have resulted in improved survival, such that
patients transplanted for chronic HBV now have comparable or
superior outcomes compared to recipients transplanted for other
chronic liver diseases [4].
Hepatitis B immune globulin (HBIG) has been central to pre-
vention strategies since the early 1990s. Although its mechanism
of action is incompletely understood, HBIG likely acts by binding
to andneutralizing circulating virions and by inhibiting cell-to-cell
infection [5]. The landmark study by Samuel and colleagues in
1993 demonstrated that the use of prolonged high dose HBIG
was associated with a signiﬁcant reduction in HBV recurrence
and improved survival [6]. This ﬁnding revolutionized post trans-
plant outcomes for those with HBV infection. The next major
advance camewith the approval of lamivudine, theﬁrst nucleoside
analogue for HBV, with a safety and tolerability proﬁle well-suited
to cirrhotics and transplant recipients [7,8]. Lamivudine alone,
however, was limited by a high rate of viral resistance and, conse-
quently, prophylactic strategies rapidly evolved to a combination
of HBIG and lamivudine. Although antiviral drugs have improved
over the years, with current entecavir and tenofovir having very
low rates of drug resistance, most transplant programs in North
America and Europe still utilize a combination of HBIG and a
nucleoside analogue for prophylaxis and this combination pre-
vents HBV recurrence inP90% of transplant recipients [9,10].
The major shortcoming of HBIG therapy has been its prohibi-
tive cost. For this reason alone, prophylactic strategies using lower
doses or limited duration of HBIG have evolved. ‘‘HBIG minimiza-Journal of Hepatology 20
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bination with nucleoside analogues have been shown to be highly
effective in preventing HBV recurrence. The Australasian Liver
Transplant Study Group reported HBV recurrence rates were only
4% at 5 years with use of low dose intramuscular HBIG (400–
800 IU monthly) in combination with lamivudine. Moreover, this
regimen was less than 10% of the cost of high dose intravenous
HBIG plus lamivudine [11]. Buti and colleagues evaluated short-
term (1 month) HBIG in combinationwith lamivudine, and among
29 patients, no recurrences were seen after 18 months [12], and a
long-term follow-up study of 14 of these patients identiﬁed only
one patient with HBV recurrence at 48 months post-LT [13]. It is
noteworthy that in both these studies, the majority of patients
received antiviral therapy at initial assessment and HBV DNA
was suppressed to undetectable levels prior to transplantation.
The efﬁcacy of antiviral therapy in patients with cirrhosis is likely
an important element of the success of prophylactic regimens
using either reduced dosing or duration of HBIG.
The strategy of active immunoprophylaxis with HBV vaccina-
tion as an alternative to HBIG in the post transplant setting has
yielded conﬂicting results [14–17]. Sanchez-Fueyo and colleagues
reported success of achieving protective anti-HBs titres (>10 IU/L)
with active immunization in 14 of 17 (82%) low risk patients [14].
In contrast, Angelico et al. reported success rates of only 18% [15].
Other data have emerged that suggest administration of either
booster doses or double dose third generation recombinant vac-
cines may enhance the vaccination response and decrease forma-
tion of escape mutants [16,17]. However, pending additional
studies with long-term follow-up, vaccination cannot be recom-
mended as an alternative to passive immunoprophylaxis.
Studies have consistently shown that the risk of recurrent
HBV infection is highest in those with HBe antigen positivity or
>100,000 copies/ml of HBV DNA present at the time of transplan-
tation [6,11,18]. Conversely, the risk is signiﬁcantly lower in
those who are HBe antigen negative and/or have low or negative
HBV DNA levels at transplantation. With current potent antiviral
therapies, most patients can achieve undetectable HBV DNA lev-
els at the time of transplantation, and thus be at low risk for
recurrent HBV. These patients are ideally suited for prophylactic
strategies that minimize HBIG use. This low risk group – HBe
antigen negative and HBV DNA undetectable – was the target11 vol. 55 j 507–509
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group for withdrawal of prophylaxis in the study by Lenci and
colleagues [19].
With the availability of potent antiviral drugs with a high
genetic barrier to resistance, one may argue that HBIG is unnec-
essary. There are no published data on the use of drugs such as
tenofovir and entecavir as monotherapy to prevent HBV recur-
rence from the time of transplantation, but limited studies have
evaluated use of these drugs after discontinuation of HBIG in
patients initially treated with combined HBIG and nucleoside
analogues therapy and high efﬁcacy is reported (only 3% HBV
recurrence) with average follow-up periods of 1.5 years [20,21].
Other studies using less potent nucleoside analogues combina-
tions (lamivudine and adefovir predominantly) but with follow-
up periods of up to 4 years report high efﬁcacy with rates of
recurrent HBV of <10% [22,23]. Interestingly, in some patients,
non-compliance rather than viral resistance was the reason for
the failure of prophylaxis. Indeed, one reason for the high efﬁcacy
of combination therapy of HBIG and nucleoside analogues may be
the ability to monitor adherence to the receipt of HBIG.
The study by Lenci et al. focused upon whether it was possible
to deﬁne a subgroup of transplant recipients who are not at risk
for HBV recurrence and in whom prophylactic therapy can be dis-
continued [19]. In a cohort of 30 subjects, all of whom were at a
low risk for recurrence (HBsAg positive, HBeAg antigen negative
and HBV DNA negative at transplant) and treated with combina-
tion HBIG and lamivudine (± adefovir) for at least 3 years,
sequential liver biopsies were performed and evaluated for the
presence of intrahepatic HBV DNA total and cccDNA. Using the
absence of intrahepatic total HBV DNA and cccDNA as a guide,
HBIG and then antiviral therapy was withdrawn in a stepwise
fashion. After a median of 28.7 months off all prophylactic ther-
apy, 83% of the cohort remained without serologic recurrence
of HBV infection. Five patients had HBV DNA recurrence but only
one patient manifested evidence of HBV disease (high HBV DNA
levels plus increased ALT activity). While the ﬁndings of this
study suggest that a rigorous assessment of HBV in the liver
may provide a mechanism of identifying transplant recipients
in whom HBV prophylaxis may be safely withdrawn, additional
prospective studies are needed to conﬁrm these results.
In apreviouslypublishedstudy, Lenci andcolleagues studied44
patients, from which the present cohort was derived, and found
only three (7%) patients tested positive for total intrahepatic HBV
DNA and only one (2%) was positive for cccDNA [24]. These results
contrast sharply with the results of other studies that found that
themajorityof serologicallyHBsAg-negative liver transplant recip-
ients on prophylactic therapy haveHBVDNAor cccDNAdetectable
in liver and/or peripheral blood mononuclear cells (PBMCs). The
high prevalence of detectable virus in these sites has supported
the use of indeﬁnite HBV prophylaxis. Roche et al. found that 20
out of 44 (45%) patients on long-term HBIG (with and without
nucleoside analogue) had persistence of HBV DNA in the serum
(18/20), PMBC (13/20), or liver (10/20) [25]. Cheung et al. found
that 67% and 33% of 12 HBsAg-negative recipients on nucleoside
analogue prophylaxis had intrahepatic HBV DNA and cccDNA
detectable, respectively [26]. Cofﬁn et al. reported that among 10
patients on combined HBIG plus nucleoside analogue therapy fol-
lowed for median 16 months post-transplantation, 90% and 23%
had HBV DNA detectable in the liver and PBMCs, respectively
[27]. Finally, theNIH-HBVLT studyof 25patients on long-termpro-
phylaxis, found that 84% and 44% of liver biopsieswere positive for
total HBV DNA and cccDNA, with up to 48 months follow-up post-508 Journal of Hepatology 201LT [28]. The signiﬁcant differences in theprevalence of cccDNAand
intrahepatic HBV DNA across studies may reﬂect differences in
patient population (HBV DNA levels at transplant, presence of
HCC), sampling variability, or the sensitivity and reliability of the
molecular techniques used in quantifying residual HBV burden.
Practically, the utility of HBV DNA and cccDNA measurements
in the liver to determine suitability for withdrawal of prophylaxis
has limitations. Repeated liver biopsies are burdensome and
assays for quantitation of intrahepatic HBV DNA and cccDNA
are not standardized. As mentioned, sampling error and variable
assay accuracy may contribute to disparities in detection of liver
HBV DNA and cccDNA across studies and highlight the challenges
in using these measurements in managing HBV transplant recip-
ients. Indeed, the study’s authors acknowledge that their molec-
ular approach is not clinically applicable. Whether measurement
of HBV DNA in PBMCs may be an alternative means of assessing
suitability for prophylaxis withdrawal is unknown. Future studies
will need to identify alternative biomarkers to identify those
patients who are candidates for withdrawal of prophylactic ther-
apy. The lessons learned regarding HBV prophylaxis from the
Lenci study and others is that an individualized approach for
the prevention of HBV recurrence can and should be utilized.
Low and high-risk groups can be deﬁned primarily by HBV DNA
levels at transplantation. Other potential factors inﬂuencing pro-
phylaxis choices may be the presence of HDV coinfection (no
effective antiviral drugs), HIV coinfection (high prevalence of
lamivudine resistance), presence of drug-resistant HBV, and the
risk of HCC recurrence (as this is a risk for recurrent HBV) [29].
The ﬁndings of the present study support the notion that low-risk
patients – those with undetectable HBV DNA at transplant – may
be candidates for withdrawal of HBIG and, more provocatively,
may possibly be candidates for withdrawal of all prophylactic
drugs. Conversely, higher risk patients – all other groups – are
better served by long-term combination low dose HBIG plus
nucleoside analogues. Certainly, the availability of effective anti-
viral ‘‘rescue’’ therapy makes reduction or elimination of prophy-
lactic drugs more feasible to consider. However, close monitoring
for recurrence of HBV is essential during and after minimization
or withdrawal of prophylactic drugs to insure prompt initiation
of antiviral therapy to prevent signiﬁcant graft damage. Although
our ability to control recurrent HBV disease is greater today than
it was a decade ago, the treatment options for chronic HBV are
not inﬁnite and multidrug-resistant HBV has been described in
transplant recipients exposed to multiple sequential HBV thera-
pies [30]. Thus, while we should continue to reﬁne prophylactic
algorithms to reduce drug costs and increase patient and provider
convenience, the current high efﬁcacy in preventing HBV should
not be compromised. Prevention of HBV infection is still the pre-
ferred strategy over managing recurrent chronic disease.Conﬂict of interest
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